-
How to develop a staph vaccine when 'the rules are different'
After multiple failed attempts at developing a vaccine against one of the most common infections, Staphylococcus aureus, researchers at the University of California San Diego have suggestions about how to fix the problem. -
Florida's plan to import drugs: 5 things to know
On Jan. 5, Florida became the first state approved by the FDA to import cheaper medicines from Canada, but the plan is facing backlash from experts in Canada and the U.S. -
Dolly Parton and Johnny Cash join Ballad's ranks — in the form of pharmacy robots
Pharmacy robots named after singer-songwriters Dolly Parton, Johnny Cash and June Carter-Cash now fill the hallways at Ballad Health's Bristol (Tenn.) Regional Medical Center. -
Mayo to launch weight loss drug telehealth service
The Mayo Clinic Diet, a weight loss program developed by the Rochester, Minn.-based health system, is launching a weight loss telemedicine service. -
Kentucky hospital temporarily closes pharmacy after fire
A mechanical fire at UK HealthCare's Good Samaritan Hospital in Lexington, Ky., led to the temporary closure of the pharmacy. -
ISMP expands high-alert drugs list
The Institute for Safe Medication Practices added tranexamic acid injection solutions to its high-alert medications list, which registers drugs linked with a high risk of causing significant harm to patients if used in error. -
5 new drug shortages in 2024
As the FDA imports a syphilis drug from France that's been in short supply since spring 2023, the FDA and American Society of Health-System Pharmacists have reported five new drug supply issues in 2024. -
Researchers probe new uses of popular weight loss, diabetes drugs
Popular medications indicated for Type 2 diabetes or chronic weight management, including Ozempic, Mounjaro and Wegovy, are dancing through a flood of research for broader indications. -
CVS to close some Target pharmacies
CVS is planning to close dozens of pharmacies inside Target stores this year, The Wall Street Journal reported Jan. 11. -
GLP-1s not linked to suicidal thoughts: Early FDA review
On Jan. 11, the FDA said it has not found a causal link between glucagon-like peptide-1 receptor agonists, such as Ozempic and Mounjaro, and suicidal thoughts. -
Concerns mount for depressive side effects linked to asthma drug
Even after the FDA issued a warning in 2020 about the adverse effects linked to Singulair, a now generic asthma drug, and strengthened its warning in 2022, physicians continue to prescribe it to millions of patients. -
Eli Lilly weight-loss drug platform draws experts' concern
Experts and industry analysts largely agree Eli Lilly's new direct-to-consumer platform will increase access to patients who may benefit from its new anti-obesity drug Zepbound, but questions are being raised surrounding appropriate care coordination and the business model behind the offering. -
FDA scolds Michigan hospital's response to drug trial error
A 6-year-old patient received three extra doses of two chemotherapies in late 2022, and the FDA sent Children's Hospital of Michigan a warning letter about the mistake. -
Zepbound shortage could be around the corner
Eli Lilly's CEO said supply of Zepbound, the drugmaker's new weight loss drug, might not meet 2024 demand. -
Ozempic not tied to pancreatic cancer risk, study suggests
Ozempic and other glucagon-like peptide-1 receptor agonists are not linked to a higher risk of pancreatic cancer compared to insulin, according to a recent study. -
Drugmaker halts study after 2 unrelated deaths
Vertex Pharmaceuticals paused a Type 1 diabetes drug trial after two patients died. The drugmaker said the deaths are unrelated to the therapy and that it is waiting on independent review before restarting the study. -
Calorie consumption may increase after patients stop taking GLP-1s: Survey
New research points to a challenge patients may face once they stop taking a GLP-1 medication: The number of calories they consume may rise. -
FDA probes 22 reports of blood cancer after CAR-T therapy
The FDA is looking into 22 reports of patients contracting blood cancer after receiving CAR-T therapy treatment. The move comes after the agency reported initial investigation efforts into cases in November. -
33 lots of hospital IV bags recalled over superpotency risk
Leiters Health has recalled 33 lots of IV bags filled with vancomycin, phenylephrine and fentanyl because the solutions might contain double the amount labeled. -
Merck to buy oncology drugmaker
Merck is acquiring South San Francisco-based Harpoon Therapeutics, an oncology drugmaker, for approximately $680 million.
Page 10 of 50